FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000490135> ?p ?o ?g. }

• W2000490135 endingPage "1775" @default.
• W2000490135 startingPage "1774" @default.
• W2000490135 abstract "In a recent report, Balestrieri et al. (1) asserted that the effect of lamivudine (3TC) against human T-cell leukemia virus type 1 (HTLV-1) at therapeutic concentrations is seen mainly on cell proliferation, with little or no direct antiviral effect. These findings are supported by biochemical studies that have shown a high level of 3TC resistance by the reverse transcriptase (RT) of HTLV-1 (3). We and others have examined the efficacy of 3TC in HTLV-1-infected patients with HTLV-1-associated myelopathy-tropical spastic paraparesis (6, 8). In most of these patients, we saw a reduction in HTLV-1 proviral DNA load following several weeks of therapy. However, in almost all cases this decline in HTLV-1 viremia was transient and most patients regained baseline HTLV-1 load titers after a while. Despite experiencing virological failure, only silent mutations and few amino acid changes in the HTLV-1 RT could be recognized after extensive analyses, which hardly could explain high levels of 3TC resistance. Furthermore, none of the HTLV-1-positive patients examined so far have developed genetic changes during therapy with 3TC in the conserved LPQG (Q151 M) or YMDD (M184V) motifs, which are associated with resistance to this drug in other lentiviruses (7). Taken together, these data suggest that HTLV-1 RT presents primary resistance to 3TC, and codons other than 151 or 184 could be implicated.In human immunodeficiency virus type 1 (HIV-1), a novel set of mutations in the RT, E44D and V118I, has been reported to produce 3TC resistance in the absence of the M184V mutation (5). In order to examine the possible role of these mutations in HTLV-1, we compared the amino acid sequence of the pol gene of HTLV-1 (GenBank {type:entrez-nucleotide,attrs:{text:D13784,term_id:221866,term_text:D13784}}D13784) and subtype B HIV-1 (HXB2; GenBank {type:entrez-nucleotide,attrs:{text:K03455,term_id:1906382,term_text:K03455}}K03455). Alignment was performed with the CLUSTAL X program. Whereas the aspartic acid at residue 44 was not found in the HTLV-1 RT, 118I was recognized as the consensus amino acid in HTLV-1.In vitro studies of HIV-1 have shown that an isoleucine at position 118 decreases the rate of 3TC incorporation, and this reduction does not depend on the presence of classical AZT mutations (M. Girouard, K. Diallo, B. Marchand, S. McCormick, M. A. Wainberg, and M. Gotte, XI Int. HIV Drug Resist. Workshop, Seville, Spain, abstr. 26, 2002). Resistance to 3TC develops when less of the drug monophosphate gets incorporated into the nascent cDNA due to steric conformation changes in the RT. In contrast, resistance to AZT and many other nucleoside analogs develops mainly as result of pyrophosphorolysis, by which there is an increased excision and removal of the incorporated chain terminator nucleotides (2). The V118I mutation produces an alteration of the structure-dependent binding in the HIV-1 RT which translates into lower affinity for 3TC. Although HIV-1 and HTLV-1 share only ∼20% of amino acid sequence identity, their RT enzymes are quite similar. In fact, RTs from almost all lentiviruses share similar tertiary structures in palm and finger domains, in spite of high divergence in their amino acid residues (4). Taking into account all these considerations, the presence of an isoleucine at codon 118 could be in part responsible for a natural 3TC resistance by HTLV-1. Biochemical and site-direct mutagenesis studies should be conducted to confirm our hypothesis. In the meantime, for the benefit of patients with HTLV-1-associated myelopathy-tropical spastic paraparesis, antiretroviral therapy should no longer include 3TC." @default.
• W2000490135 created "2016-06-24" @default.
• W2000490135 creator A5001667792 @default.
• W2000490135 creator A5009751300 @default.
• W2000490135 creator A5013971942 @default.
• W2000490135 creator A5019171058 @default.
• W2000490135 date "2003-05-01" @default.
• W2000490135 modified "2023-10-12" @default.
• W2000490135 title "Lamivudine Resistance in Human T-Cell Leukemia Virus Type 1 May Be Due to a Polymorphism at Codon 118 (V→I) of the Reverse Transcriptase" @default.
• W2000490135 cites W2043546803 @default.
• W2000490135 cites W2043616119 @default.
• W2000490135 cites W2114908540 @default.
• W2000490135 cites W2116093796 @default.
• W2000490135 cites W2140707155 @default.
• W2000490135 cites W2154916896 @default.
• W2000490135 cites W2156456511 @default.
• W2000490135 cites W2163856239 @default.
• W2000490135 doi "https://doi.org/10.1128/aac.47.5.1774-1775.2003" @default.
• W2000490135 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/153342" @default.
• W2000490135 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12709359" @default.
• W2000490135 hasPublicationYear "2003" @default.
• W2000490135 type Work @default.
• W2000490135 sameAs 2000490135 @default.
• W2000490135 citedByCount "11" @default.
• W2000490135 countsByYear W20004901352014 @default.
• W2000490135 countsByYear W20004901352018 @default.
• W2000490135 countsByYear W20004901352019 @default.
• W2000490135 countsByYear W20004901352020 @default.
• W2000490135 countsByYear W20004901352022 @default.
• W2000490135 crossrefType "journal-article" @default.
• W2000490135 hasAuthorship W2000490135A5001667792 @default.
• W2000490135 hasAuthorship W2000490135A5009751300 @default.
• W2000490135 hasAuthorship W2000490135A5013971942 @default.
• W2000490135 hasAuthorship W2000490135A5019171058 @default.
• W2000490135 hasBestOaLocation W20004901352 @default.
• W2000490135 hasConcept C104317684 @default.
• W2000490135 hasConcept C105580179 @default.
• W2000490135 hasConcept C156719811 @default.
• W2000490135 hasConcept C159047783 @default.
• W2000490135 hasConcept C176990463 @default.
• W2000490135 hasConcept C2522874641 @default.
• W2000490135 hasConcept C2777869810 @default.
• W2000490135 hasConcept C2780593183 @default.
• W2000490135 hasConcept C49105822 @default.
• W2000490135 hasConcept C54355233 @default.
• W2000490135 hasConcept C86803240 @default.
• W2000490135 hasConceptScore W2000490135C104317684 @default.
• W2000490135 hasConceptScore W2000490135C105580179 @default.
• W2000490135 hasConceptScore W2000490135C156719811 @default.
• W2000490135 hasConceptScore W2000490135C159047783 @default.
• W2000490135 hasConceptScore W2000490135C176990463 @default.
• W2000490135 hasConceptScore W2000490135C2522874641 @default.
• W2000490135 hasConceptScore W2000490135C2777869810 @default.
• W2000490135 hasConceptScore W2000490135C2780593183 @default.
• W2000490135 hasConceptScore W2000490135C49105822 @default.
• W2000490135 hasConceptScore W2000490135C54355233 @default.
• W2000490135 hasConceptScore W2000490135C86803240 @default.
• W2000490135 hasIssue "5" @default.
• W2000490135 hasLocation W20004901351 @default.
• W2000490135 hasLocation W20004901352 @default.
• W2000490135 hasOpenAccess W2000490135 @default.
• W2000490135 hasPrimaryLocation W20004901351 @default.
• W2000490135 hasRelatedWork W1487857142 @default.
• W2000490135 hasRelatedWork W1974674628 @default.
• W2000490135 hasRelatedWork W2048790749 @default.
• W2000490135 hasRelatedWork W2068216398 @default.
• W2000490135 hasRelatedWork W2100307468 @default.
• W2000490135 hasRelatedWork W2116464980 @default.
• W2000490135 hasRelatedWork W2135124387 @default.
• W2000490135 hasRelatedWork W2155121350 @default.
• W2000490135 hasRelatedWork W2398300531 @default.
• W2000490135 hasRelatedWork W2401663930 @default.
• W2000490135 hasVolume "47" @default.
• W2000490135 isParatext "false" @default.
• W2000490135 isRetracted "false" @default.
• W2000490135 magId "2000490135" @default.
• W2000490135 workType "article" @default.